View Older Stories View More Recent Stories
-
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
-
Covid Apollo Project Makes Investment in Rhinostics to Accelerate Covid-19 Testing Volumes Through High Throughput Sample Accessioning
-
AavantiBio Bolsters Leadership Team with Appointment of Ty Howton as Chief Operating Officer and General Counsel
-
Form SC 13G ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use
-
Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology
-
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer
-
Form SC 13D/A Satsuma Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
-
DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA Therapeutics
-
Satsuma Pharmaceuticals Inc. (STSA) Announces $80 Million Private Placement Financing
-
Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing
-
PepGen Announces Formation of Scientific Advisory Board
-
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
-
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
-
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
-
Form SC 13D Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G ImmunoGen, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Atea Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Frazier Lifesciences Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CURIS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Akouos, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Inozyme Pharma, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Olema Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Trillium Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ChemoCentryx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G 5:01 Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G BCLS Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Kinnate Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Lyra Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CONCERT PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Verastem, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Travere Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Pandion Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Silverback Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Larimar Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G NOVAVAX INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.


